Latest Operating Expenses News

Global X FANG+ ETF reported a sharp decline in annual profit, while its net asset value fell by more than 10% after 30 June as underlying technology stocks weakened. The audited fund still grew net assets to AUD1.606 billion and declared a 235.84 cents-per-unit distribution.

Global X China Tech ETF reported an AUD15.727 million profit for the year ended 30 June 2026, powered by gains in listed Chinese technology investments. But the fund disclosed that its net asset value has since fallen by more than 10%, leaving the audited result looking increasingly historical.

Global X S&P Biotech ETF (ASX:CURE) reported a AUD22.601 million profit for the year to 30 June 2026, reversing the prior year’s AUD2.863 million loss. The turnaround was driven overwhelmingly by gains in listed biotech securities and foreign exchange, rather than recurring income.

Global X Artificial Intelligence Infrastructure ETF (ASX:AINF) reported a $25.291 million profit for its first full financial year, driven overwhelmingly by investment gains. Net assets climbed to $169.603 million after almost $147.2 million of new unit applications, while the fund paid a 61.64 cents per unit distribution.

Global X Battery Tech & Lithium ETF delivered a sharply higher profit for the year ended 30 June 2026, driven by large fair-value gains across its listed equity portfolio. But the fund says its net asset value has since fallen by more than 10% as underlying battery and lithium investments weakened.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Frontier Digital Ventures has shrunk its top line by 27% as it exits low-margin businesses, but the reset delivered higher EBITDA, a 17% margin and near-total free cash flow conversion in the first half of FY2026. The next test is whether pricing and cost discipline can lift earnings without further customer erosion.

Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.

Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.

Dataworks Group has lodged a prospectus for a non-renounceable entitlement offer targeting A$1.24 million, alongside a committed A$3 million placement. The raising would fund debt repayment, working capital and contract mobilisation, but also materially expand the company’s share count and option pool.

JPMorgan Equity Premium Income ETF reported a sharp fall in operating profit as fair-value losses overwhelmed higher distribution income. The fund will also switch its underlying ETF from NYSE Arca to a London-listed vehicle, while keeping its stated investment objective and total management fees and costs unchanged.

JPMorgan Global Select Equity Fund reported A$39.1 million in operating profit for the year ended 30 June 2026, with net assets rising to A$578.3 million. The result includes fair value gains and comes with a concentrated portfolio, with 100% of fair value investments tied to the underlying JPMorgan Global Select Equity ETF.